Thon, Niklas <br/><br/>
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.  [electronic resource] 

 -  Journal of neurology  Feb 2017 
 - 350-358 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-1459 
<br/><br/><label>Standard No.: </label>10.1007/s00415-016-8355-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--therapeutic use<br/>Biopsy<br/>Central Nervous System Neoplasms--diagnosis<br/>Chemoradiotherapy<br/>DNA Methylation<br/>DNA Modification Methylases--genetics<br/>DNA Repair Enzymes--genetics<br/>Dacarbazine--analogs & derivatives<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--diagnosis<br/>Humans<br/>Longitudinal Studies<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Promoter Regions, Genetic<br/>Prospective Studies<br/>Salvage Therapy<br/>Temozolomide<br/>Tumor Suppressor Proteins--genetics<br/>Young Adult